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On the effect of vitamin C intake on human health: How to (mis)interprete
the clinical evidence
Jens Lykkesfeldt
Faculty of Health & Medical Sciences, University of Copenhagen, DK-1870, Frederiksberg C, Denmark
A B S T R A C T
For decades, the potential beneficial effect of vitamin C on human health—beyond that of preventing scurvy—has been subject of much controversy. Hundreds of
articles have appeared either in support of increased vitamin C intake through diet or supplements or rejecting the hypothesis that increased intake of vitamin C or
supplementation may influence morbidity and mortality. The chemistry and pharmacology of vitamin C is complex and has unfortunately rarely been taken into
account when designing clinical studies testing its effect on human health. However, ignoring its chemical lability, dose-dependent absorption and elimination
kinetics, distribution via active transport, or complex dose-concentration-response relationships inevitably leads to poor study designs, inadequate inclusion and
exclusion criteria and misinterpretation of results. The present review outlines the differences in vitamin C pharmacokinetics compared to normal low molecular
weight drugs, focusses on potential pitfalls in study design and data interpretation, and re-examines major clinical studies of vitamin C in light of these.
1. Introduction
Countless clinical studies have investigated the effects of vitamin C
on human health ever since the identification of its role in the pre-
vention of scurvy. These can roughly be divided into i) mechanistic
studies investigating the pharmacokinetics of vitamin C, its homeostasis
and the role of ascorbate in various physiological processes, ii) epide-
miological studies exploring associations between vitamin C intake or
status and morbidity and mortality, and finally iii) intervention studies
examining the effect of vitamin C supplementation on disease preven-
tion, progression and treatment. Despite this wealth of scientific evi-
dence, some very basic albeit fundamental questions remain un-
answered to this day including: “What is the optimal intake of vitamin C?”
and “What is the preventive and therapeutic potential of vitamin C?”
A major reason for the continued controversies about the putative
importance vitamin C in human health can be found in the inter-
pretation and quality of the available clinical data. Randomized con-
trolled trials (RCTs) are generally considered the gold standard in drug
efficacy and safety testing. Naturally, the RCT paradigm has been ap-
plied to micronutrient studies in search of clinical support for a possible
functional health benefit of dietary supplementation. For vitamin C,
such intervention studies have with few exceptions been unsuccessful
showing only minor or no effects on morbidity and mortality [1].
However, vitamin C differs significantly from the typical low molecular
weight pharmaceutical drug in a number of ways that need to be in-
corporated into study designs and interpretation to achieve valid con-
clusions [2]. Epidemiological studies on the other hand are often ac-
cused of suffering from potential selection bias and confounding.
Moreover, their lack of ability to establish causality and discriminate
between multiple etiological sources may suggest the possibility that
identified associations be merely coincidental or secondary with respect
to vitamin C status per se [3].
As humans do not have the capacity to synthesize vitamin C in
contrast to the vast majority of mammalian species, its pharmacoki-
netics has been devoted particular attention as a basis for the evaluation
of uptake, distribution, metabolism and clearance. Other species po-
tentially have the capacity to increase biosynthesis of vitamin C in times
of need. However, in humans, increased turnover—due to e.g. diseased-
induced inflammation or oxidative stress—can only be compensated by
increased intake or by supplementation.
One important aspect of dose selection in intervention studies is the
assumption of near 1st order kinetics within the therapeutic range. For
vitamin C, convincing data were published decades ago indicating that
vitamin C pharmacokinetics is in fact highly dose-dependent in humans
within the physiological range [4,5]. Despite this important break-
through, the consequences of these observations and the true com-
plexity of vitamin C homeostasis did not become evident until the
identification of the sodium-dependent vitamin C transporters (SVCTs).
The SVCTs are now considered the primary means of systemic control
of vitamin C homeostasis and are capable of actively transporting as-
corbate into cells against a considerable concentration gradient [6]. The
resulting dose-dependency and non-linearity of the pharmacokinetics
profoundly changes fundamentals of study design and data interpreta-
tion but unfortunately, this reality has mostly been neglected in the
clinical vitamin C literature.
While not attempting to answer the highly pertinent questions listed
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above as insufficient evidence is available, the purpose of this review is
to discuss the pharmacology of vitamin C and to critically re-examine
the larger studies from the clinical literature on vitamin C in light of the
potential pitfalls that may lead to misinterpretations.
2. Pharmacokinetics of vitamin C
The pharmacokinetics of vitamin C has recently been reviewed in
detail [7] and only a brief overview is provided here. The intestinal
absorption of orally ingested vitamin C—that being from food sources
or supplements alike—occurs through transporter proteins rather than
by passive diffusion [8,9]. Several decades ago, it was observed by
independent investigators that increasing oral doses beyond
200–400 mg vitamin C/day leads to decreasing absorption fractions
and it was concluded that intestinal vitamin C absorption is subject to
saturable active transport [4,5]. Levine and coworkers later performed
a series of meticulous pharmacokinetic studies in healthy young men
and women showing that plasma saturation occurs at a concentration
around 70–80 μM [10,11] (Fig. 2H). Other studies have arrived at the
same number [12,13]. This phenomenon also accounts for the highly
different pharmacokinetics of vitamin C following oral vs. parenteral
administration (reviewed in more detail in Ref. [7]). It became known
that dehydroascorbic acid (the oxidized form of vitamin C) has the
ability to pass through a number of glucose transporters by facilitated
diffusion [14–17], but this realization did not explain the dose-de-
pendency following oral ingestion. Later, it was discovered that ascor-
bate (the reduced form of vitamin C) and dehydroascorbic acid are
taken up by separate mechanisms in the intestine and that uptake of
ascorbate is sodium dependent [18]. This coincided with the discovery
and characterization of the sodium-dependent vitamin C transporter
(SVCT) family by Tsukaguchi and coworkers [6], who later found that
the intestine contains the low affinity/high capacity active transporter
SVCT1 [19]. Moreover, SVCT1 is also present in the epithelium of the
proximal renal tubuli and governs the active reabsorption of ascorbate
in the kidneys [19]. It has been shown in Slc23a1−/− mice lacking the
SVCT1 that renal fractional excretion increases up to 18-fold, while
intestinal absorption is not significantly diminished [20]. This suggests
that the renal SVCT1-mediated reabsorption of ascorbate is pivotal in
the maintenance of systemic vitamin C homeostasis. The active trans-
porter displays dose-dependency and its expression may be regulated
by vitamin C status in several tissues [8,21,22].
Several single-nucleotide polymorphisms (SNPs) have been identi-
fied in the human SVCT1. Most of these are suggested to lead to a lower
homeostatic set point, but reliable data on vitamin C kinetics from these
subpopulations are difficult to obtain due to the rare occurrence of
some of the individual SNPs and so far, very limited data are available.
However, a few studies have suggested that such SNPs may be linked to
increased disease risk. Thus, Zanon-Moreno et al. found significant as-
sociations between the rs1279386 SNP in SLC23A2 and lower plasma
vitamin C concentrations as well as increased risk of glaucoma [23].
SNP rs6596473 of SLC23A1 has been suggested to be associated with
aggressive periodontitis [24]. Kobylecki et al. investigated a SNP
rs33972313 that provide higher vitamin C concentration than the
wildtype in a Mendelian randomization study of cardiovascular mor-
tality and morbidity. They concluded that their data “cannot exclude
that a favorable effect of high intake of fruit and vegetables could in
part be driven by high vitamin C concentrations” [25]. In other words,
although the data were not conclusive, they indicated that the SNP
could be associated with improved cardiovascular health. Interestingly,
Corpe et al. modelled dose vs. concentration curves for a selected
number of known SNPs and found that the functionally poorest SVCT
allele identified (A772G, rs35817838) was expected to result in a
plasma saturation level corresponding to life-long vitamin C deficiency
[20]. However, these modelling studies and their potential phenotypic
consequences remain to be confirmed in clinical studies.
Distribution of vitamin C from plasma to tissues are primarily
governed by the SVCT2, i.e. the low-capacity high-affinity version of
the vitamin C transporter. It is located in most cell types and it appears
that local concentrations and/or isoforms of the transporter determine
the steady state concentration of the individual organ/tissue [7]. From
Fig. 1. Distribution of vitamin C is highly
differential between organs of the body.
Several organs have concentration-depen-
dent mechanisms for retention of vitamin C
maintaining high levels during times of in-
adequate supply at the expense of other
organs. Particularly protected is the brain.
In addition, the concentration-dependent
absorption and re-absorption mechanisms
contribute to the homeostatic control of the
vitamin C in the body. Reproduced from
Ref. [7].
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detailed studies in guinea pigs (that like humans are unable to syn-
thesize vitamin C), it is known that differences in expression levels of
SVCTs leads to a highly diverse distribution of vitamin C between or-
gans (See Fig. 1) [21,22]. Thus, up to 20-fold difference in steady state
concentration has been measured between e.g. brain/adrenal gland and
kidney/heart/muscle being among tissues with the highest and lowest
in steady state concentrations, respectively [26–31].
Metabolism of vitamin C is intimately linked to its redox status.
Ascorbate is an efficient chain-breaking antioxidant both capable of
quenching free radicals and specifically donating electrons to a con-
siderable number of mono- and dioxygenase enzymes [32]. Moreover, a
whole range of mechanisms has evolved to ensure that oxidized vitamin
C is almost quantitatively salvaged by intracellular recycling of its
oxidized form back to the biologically active reduced form ascorbate by
a variety of cell types [33–42]. Thus, the daily turnover of vitamin C in
healthy non-smoking individuals has been estimated to a mere 3% [43],
thereby grossly limiting the daily amount necessary to be ingested to
maintain sufficiency. Moreover, it has been estimated in both in vitro
and in vivo studies that erythrocytes are capable of recycling the total
amount of vitamin C present in blood approximately once every 3 min
[28,33]. Combined with the dose-dependent renal reuptake, the re-
cycling of dehydroascorbic acid to ascorbate are instrumental in
maintaining vitamin C homeostasis in the body [7,44].
Parenteral administration of vitamin C bypasses the intestinal
Fig. 2. Comparison of vitamin C and an
average low molecular weight drug with re-
gard to plasma concentration. Left panels
illustrates intravenous administration, right
panels oral administration, respectively.
Schematic plasma concentration vs time
following a bolus and maximal plasma con-
centration vs dose plots are compiled from
data in Refs. [7,10,11,27,48,49,54,94–97].
Plots are approximations for illustrative
purposes only. A: An average drug displays
1st order kinetics following i. v. administra-
tion with a constant elimination half-life. B:
Oral administration gives rise to an absorp-
tion phase followed by a 1st order elimina-
tion with a half-life similar to that of i. v.
administration. C: Intravenous administra-
tion of vitamin C typically results in 1st ki-
netics until the physiological concentration
range is reached where the elimination will
gradually decline. D: The effect of oral ad-
ministration of vitamin C on the plasma
concentration will depend considerably on
the vitamin C status of the individual. Vi-
tamin C deficiency will promote quantitative
uptake while vitamin C sufficiency will pro-
mote excretion with little impact on the
plasma concentration profile. E & F: For the
average drug, the maximal plasma con-
centration is proportional to the dose re-
gardless of route of administration. G: A re-
cent compilation of i. v. data revealed that
the maximal plasma concentration following
i. v. administration of vitamin C is propor-
tional to the (infusion) dose up to about
50 mmol/L (corresponding to a dose of 70 g/
m2 after which is does not increase further
[7]. H: Plasma Cmax following oral adminis-
tration of vitamin C is not proportional to the
dose but displays saturation kinetics [11,98].
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absorption and thus the saturable transport mechanism that limits the
achievable plasma concentrations [45–47]. In contrast to oral admin-
istration, intravenous infusion of administration of 5–70 g of vitamin C
produces a predictable plasma concentration and studies have shown
that i. v. administration within this dose range adheres to 1st order
kinetics with a constant half-life of about 2 h [48,49]. Intravenous
administration of pharmacological doses of vitamin C gives rise to
millimolar plasma concentrations that are not achievable by oral ad-
ministration. Pharmacological doses of vitamin C are currently being
evaluated in both sepsis and cancer therapy [50–53].
3. Vitamin C vs. ‘normal’ low molecular weight drugs
The pharmacokinetic properties of vitamin C—as briefly outlined
above—renders its dose vs concentration relationship quite different
from that of a typical low molecular weight drug. Fig. 2 illustrates the
differences between vitamin C and an ‘average low molecular weight
drug’ with respect to plasma concentration vs time and plasma steady-
state concentration vs dose as well as dependency on administration
route. Elimination and steady state concentrations in tissues are illu-
strated in Fig. 3. Commonly, drugs display 1st order kinetics resulting in
a predictable plasma and tissue concentration depending proportionally
on the dose and irrespective of route of administration (Fig. 2A, B, 2E
and 2F). In contrast, vitamin C shows mixed kinetics following oral
administration (Fig. 2D), and mainly 1st order kinetics following in-
travenous administration until near-physiological levels are reached
(Fig. 2C). There is a clear dose-dependency of oral administration
(Fig. 2H) reaching a maximum level of about 70–80 μmol/L.
Surprisingly, although displaying 1st order kinetics of over a wide
range, intravenous administration may also reach a maximum level
around 50 mmol/L at doses higher than 70 g/m2 [7]. Importantly, the
data supporting the highest concentrations in Fig. 2G come from only a
single study [48]. Table 1 summarizes basic pharmacokinetic proper-
ties, i.e. absorption, distribution, metabolism and excretion as well as
modelling options of an average pharmaceutic drug compared to those
of vitamin C. Evidently, the dose-dependency of vitamin C transport
have profound impact on its pharmacology. More importantly, some
essential points can be extracted from this information. Firstly, the
potential efficacy of vitamin C intervention in humans is intimately
linked to the vitamin C status of the individual at study start. Thus,
people without some degree of vitamin C deficiency or inadequacy are
very unlikely to benefit from further supplementation/intake. Secondly,
multiple epidemiological studies have shown that for most parts of the
World, the majority of the population ingests adequate amounts of vi-
tamin C through their diet. Therefore, unfocussed clinical trials not
using poor vitamin C status as inclusion criterion are highly unlikely to
produce a measurable clinical effect. The fact that overshooting the
homeostatic point of saturation around 70 μmol/L in plasma only
produces a very short-lived increase in body vitamin C has been mostly
ignored in the clinical literature [54]. Indeed, a re-examination of the
35 randomized controlled trials from a systematic review of vitamin C
efficacy using mortality as endpoint [55] revealed that none of the
studies had incorporated vitamin C status into their inclusion criteria
and only one study indicated some degree of suboptimal vitamin C
status prior to intervention [2].
Fig. 3. Comparison of vitamin C and an
average low molecular weight drug with
regard to tissue concentration. Plots are
approximations for illustrative purposes
only. A: Following administration, a normal
drug will quickly distribute to the tissue by
passive diffusion until equilibrium is
reached. Subsequently, the drug is cleared
from the tissue with a half-life equal to that
of plasma elimination [97]. B: The maximal
tissue concentration is proportional to the
dose. C & D: In a vitamin C sufficient in-
dividual, tissue concentration will be at
their steady state and not subject to sig-
nificant fluctuation unless an insufficient
dose is provided. The maximal tissue con-
centration of individual tissues depends on
SVCT configuration and expression and
display saturation kinetics with increasing
doses [7,10,11]. E: In a vitamin C deficient
individual, tissue concentrations will
quickly increase when vitamin C is provided
depending on SVCT2 expression and tissue
priority [7]. If vitamin C administration is
discontinued, the tissue concentration will
gradually decline but much slower than
from the plasma compartment. Some tissues
such as the brain have a remarkable ability
to retain vitamin C against an increasing
concentration gradient as a result of emer-
ging deficiency [92,99]. F: In a vitamin C
deficient individual, steady state level will
be reached when sufficient vitamin C is
provided. Steady state concentration of the
tissue does not exceed saturation level.
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4. Pitfalls in the design and interpretation of clinical studies of
vitamin C
Several pitfalls and design challenges are involved in the assessment
of the effect of vitamin C in health and disease. Some major factors have
been summarized in Table 2. Epidemiological studies lack the ability to
establish causal relationships and have generally not been highly va-
lued in the hierarchy of clinical evidence. Confounding is an inheritable
risk in observational studies and for micronutrient studies such as those
with vitamin C, the risk of contributions from multiple or unknown
deficiencies is evident and essentially impossible to definitively adjust
for. Thus, identified associations between poor vitamin C status and
increased risk of disease or mortality may in fact be causally related to
other factors not accounted for in the study. However, in contrast to the
general notion, a detailed evaluation of randomized controlled trials
(RCTs) and observational studies examining the same clinical topic
revealed that well-designed observational studies did not systematically
overestimate the magnitude of the effects of treatment as compared
with those in RCTs [56].
4.1. Measuring vitamin C intake vs status
A possible contributor to erroneous conclusions in cohort studies is
the focus on vitamin C intake rather than vitamin C status. Many cohort
studies—including the largest ones—have used estimates of micro-
nutrient intakes compiled from self-reported food frequency ques-
tionnaires (FFQs) or food diaries as their basis for correlations between
vitamin C intake and disease risk (Table 3). However, as pointed out in
the above, there is not a linear relationship between vitamin C intake
and status. Even more importantly, the relationship between vitamin C
intake and plasma/tissue homeostasis depends significantly on the vi-
tamin C status of the individual, which is only assessable through
Table 1
Typical pharmacokinetic properties of an orally administered pharmaceutical drug vs. those of vitamin C obtained from food sources or supplements (modified from
Refs. [3]).
Pharmacokinetic property Typical orally administered low molecular weight drug Vitamin C from food sources or supplements
Absorption 1st order absorption kinetics within the therapeutic range. Absorption
through passive transport resulting in plasma concentrations in the nano-
to micromolar range.
Nonlinear absorption kinetics due to a mixture of saturable active
transport through SVCT1 and facilitated diffusion through GLUT
transporters resulting in micromolar plasma concentrations and
millimolar tissue concentrations.
Distribution Primarily distributed through passive diffusion. Immediate distribution
primarily determined by blood flow and tissue perfusion. Homeostasis
largely based on physical-chemical properties of the drugs including
lipofilicity, pKa and protein binding.
Primarily distributed through active transport. Immediate distribution
based on tissue priority governed by SVCT2 transporter expression and
saturation kinetics. Homeostasis depends on adequacy of dose and
vitamin C status of bodily compartments.
Metabolism Catabolized unspecifically by phase I & II enzymes potentially generating
a range of metabolites and/or conjugates with increased water solubility.
Specifically and unspecifically oxidized through electron donor and
antioxidant properties, respectively, but efficiently regenerated
intracellularly to its reduced form by numerous cell types.
Excretion Most often 1st order elimination kinetics though passive glomerular
filtration and passive reabsorption depending on pKa. Overall relatively
rapid excretion of parent compound and metabolites through urine and
bile.
Nonlinear concentration-dependent elimination kinetics resulting in
anything from 0 to 100% active renal reabsorption depending on vitamin
C availability and saturation of bodily compartments.
Modelling Kinetics can usually be modelled well by simple compartment and non-
compartment models.
Does not comply with the basic assumption of terminal 1st order kinetics
used in both compartmental and non-compartmental analysis.
Table 2
Summary of the most important design challenges in clinical studies of vitamin C in health and disease leading to potential misinterpretation of the results and
erroneous conclusions.
Study type Design challenges Potential pitfall in interpretation
Observational studies Confounding Vitamin C deficiency is commonly accompanied by other micronutrient deficiencies, suboptimal
lifestyle and other residual confounding that may potentially contribute to or even be
responsible for the observed associations.
Using vitamin C intake as surrogate marker for
vitamin C status
Vitamin C intake is a poor surrogate for vitamin C status as the estimation of vitamin C intake is
inherently inaccurate and the relationship between intake and status is highly complex.
Randomized controlled
trials
Subjects already high in vitamin C at study start Due to the saturation kinetics of vitamin C following oral administration, individual vitamin C
status greatly affect the potential effect of supplementation. As vitamin C deficiency is most
commonly limited to selected subpopulations, the potential efficacy will be effectively diluted if
inclusion criteria are not taking this into account.
Placebo group continues to take supplements Allowing continued supplement intake in the placebo group will test two doses of vitamin C
against each other rather than the effect of vitamin C supplementation per se. Because of
saturation kinetics, this will further diminish the possibility of identifying effects of the vitamin
C intervention.
Both intervention and placebo groups have had
a lifelong preload with vitamin C
The human diet typically contains from 0 to 250mg vitamin C per day not considering
supplementation, i.e. a wide range and with the high end being within the range or even
exceeding that of several of the large intervention studies. Thus, the potential for observing
disease prevention with supplementation vs placebo during the study period should be
compared to the lifelong vitamin C status of all study subjects.
Vitamin C is not tested as a single supplement Not testing vitamin C as a single supplement limits the possibility of extracting its effect per se.
All studies Selection bias Recruitment may favor health-conscious, self-motivated subjects eating a healthy diet already
high in micronutrients and with a lower disease rate than background population. This will limit
the possibility of identifying effects of supplementation.
Using non-fasted blood samples Oral vitamin C intake produces a transient albeit significant increase in plasma level depending
on the vitamin C status of the individual (See Fig. 2D for example). This will lead to larger
variation and may result in an artefactually high average vitamin C concentration.
Inadequate sample handling Inadequate sampling stabilization and handling leads to increased post sampling oxidation and
artefactually low vitamin C concentrations regardless of methodology.
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plasma analysis. Moreover, FFQs suffer from lack of precision and ac-
curacy due to e.g. human recall error, inability to account for vitamin
loss from storage and preparation of foods as well as not accounting for
polymorphisms possibly affecting vitamin C homeostasis [1,57–60]. In
order words, information from FFQs is inadequate to establish the true
vitamin C status of the individual and will at the very least be en-
compassed with increased variability and thus increased risk of type 2
errors. Also, most cohort studies only collect information at baseline
and consequently do not take changes in diet over time into account.
However, plasma vitamin C status per se may also fluctuate con-
siderably immediately following food or supplement ingestion [54].
Consequently, the most reliable and practically available information
on vitamin C status can only be retrieved from a blood sample from a
fasted individual. This requirement is clearly not met by most ob-
servational studies.
4.2. Instability of vitamin C
Even if fasted blood samples can be obtained, there may still be
significant challenges in correlating vitamin C status to disease risk.
This is due to the lability of ascorbate ex vivo. Ascorbate is quickly
oxidized ex vivo and the resulting oxidation products are quickly de-
graded or metabolized [13], rendering the analytical recovery too low.
To complicate things even more, the oxidation of vitamin C in solution
is concentration dependent [61,62]. Hence, in order to obtain valid
vitamin C concentrations, meticulous sample handling is critical
[63–66]. Typically, blood/plasma/serum samples retrieved from bio-
banks have not been specifically stabilized and stored with the inten-
tion of analyzing vitamin C and therefore not been handled appro-
priately to prevent post sampling oxidation. Consequently—and in this
authors personal experience—generic biobank samples are rarely if
ever suitable for proper quantification of vitamin C. Finally, the analysis
of vitamin C has been performed by a variety of methodologies some of
which are based on derivatization procedures giving rise to degradation
as well as detection of a number of specimens unrelated to vitamin C. As
reviewed by others, robust quantification of ascorbate is achieved by
high-performance liquid chromatography using electrochemical detec-
tion [67].
4.3. Design problems in RCTs
RCTs are considered the gold standard for testing drug efficacy and
safety. However, for testing efficacy in chronic disease prevention of
micronutrients already present in the body in considerable concentra-
tions, the RCT as design concept is subject to a number of challenges
[68–72]. Micronutrient studies are most often conducted as primary
disease prevention studies with lower statistical power than secondary
prevention studies. Such studies may require very long intervention
periods to accumulate sufficient disease endpoints [1]. This perspective
may then be compared to the accumulated preventive potential of a
lifelong vitamin C intake of both placebo and intervention groups up to
the trial. The Nurses’ Health study collected dietary information on
85118 female nurses and estimated their diets to contain between 61
and 209 mg vitamin C/day (median intake in lowest vs. highest quin-
tile) [73]. This suggests that a considerable proportion of the subjects
recruited for intervention studies may have ingested more vitamin C
than the trial supplement for many years prior to enrolment. Un-
fortunately, the impact of this potential bias has been completely ne-
glected in the available literature.
Moreover, RCTs should include a placebo group. Given the chal-
lenges discussed above, it is highly questionable if this is possible in
studies with micronutrients including vitamin C. In addition to this,
several of the largest intervention studies with vitamin C have allowed
the so-called ‘placebo group’ to continue to take supplements up to the
levels of the current RDAs during the entire trial period ([74–76]; see
Table 5). For vitamin C, this suggests that the individuals of the placebo
groups could have ingested up to about 350 vitamin C mg/day and still
been considered control subjects. In most cases, the frequency of con-
current supplementation in the placebo group has not been recorded
but the Women's Antioxidant Cardiovascular Study reported that 27.5%
of the placebo group took concurrent supplements [74]. Also from the
plasma concentrations reported in the placebo group, it is apparent that
the placebo group was already well within the saturation range with an
average of 71.5 μmol/L [74]. As mentioned earlier, vitamin C displays
dose-dependent kinetics reaching saturation around 70 μmol/L. Based
on this, any significant outcome of such an intervention study would be
a surprise. Effectively, intervention studies with vitamin C do not have
a true placebo group but rather compare effects of two doses of vitamin
C that in many cases are not very different and in terms of subject vi-
tamin C status will result in largely overlapping populations. Collec-
tively, this entails that the potential for intervention efficacy in these
trials has generally been very low. Unfortunately, the possible benefit in
individuals with poor vitamin C status at entry may therefore be diluted
beyond identification.
More general challenges with clinical studies of vitamin C include
the potential selection bias when people are recruited through adver-
tisement. The “healthy enrollee effect” in micronutrient studies is well-
known and describes the tendency towards recruitment of health-con-
scious, self-motivated subjects eating a healthy diet already rich in
micronutrients and with higher exercise frequency and lower disease
rate than background population [70,77]. Also, as vitamin C is highly
redox active and thus a labile compound, sample handling is critical
and requires special attention in particular in large multicenter trials
[63–66]. Poor attention to sample stability issues will result in lower
vitamin C values due to loss during workup. In contrast, obtaining
samples from individuals in the non-fasted state will result in artefac-
tually elevated steady state levels (Table 2).
5. Re-examining the clinical evidence
In the following, the largest clinical studies on vitamin C are re-
examined in view of the information included in Tables 1 and 2. For
practical reasons, this review only reexamines the five largest studies in
each category. These studies may be considered the most influential in
terms of authoritative impact and serves to illustrate the challenges in
the literature on vitamin C rather than providing an exhaustive sys-
tematic review.
5.1. Prospective cohort studies estimating vitamin C intake
A considerable number of observational studies have examined the
relationship between vitamin C and morbidity and mortality for dec-
ades. The largest of all studies of vitamin C and disease are all cohort
studies estimating disease risk/mortality in relation to vitamin C intake
using FFQs and food diaries rather than by measuring vitamin C status
per se. Consequently, they all suffer from the problems in relating es-
timated intake to actual vitamin C status of the individual. The studies
are listed in Table 3.
The Nurse’ Health Study examined the association between vitamin
C intake and supplementation on the risk of chronic heart disease [73].
They found both a significant inverse correlation between vitamin C
intake and chronic heart disease but also a positive association to
supplement use. A semi-quantitative FFQ was used to assess micro-
nutrient intake including supplements four times during the follow-up
period. As acknowledged by the authors, a major weakness of the study
was that the population was well-nourished as shown e.g. by the esti-
mated median vitamin C intake of the non-supplement users of 132 mg/
day, which amounts to more than twice the RDA at the time of the
study. Thus, the study does not provide insight to the possible benefit in
individuals with low vitamin C status or risk factors of CVD.
The French E3N study assessed the possible association between
estimated vitamin C intake from both food and supplements and risk of
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postmenopausal breast cancer in a cohort of healthy women primarily
comprising teachers [78]. The study found no overall association be-
tween vitamin C supplementation and breast cancer but surprisingly,
the top quartile of vitamin C intake from food only showed increased
risk of breast cancer suggesting a possible U- or J-shaped relationship. A
self-developed FFQ was used to estimate nutrient intake and in a vali-
dation study not described in detail, the correlation coefficients for
vitamin C intake were 0.73 for reproducibility and 0.55 for validity,
which is rather low. Unfortunately, the FFQ was not validated towards
vitamin C status as thus not particularly well suited for this purpose.
Whereas vitamin C supplementation was assessed several times through
follow-up, the estimated vitamin C intake from food was only estimated
at a single baseline time-point. Thus, a part from the limitation of being
based on FFQs, the study does not account for any dietary changes over
the 10 year follow-up period.
In the Health Professionals Follow-up Study [79], the possible re-
lationship between estimated vitamin C intake and risk of stroke was
examined in healthy men. The study reported no association between
either vitamin C intake or supplementation and risk of stroke after eight
years. Vitamin C intake from food and supplements was assessed
biannually using FFQs. As with the studies mentioned above—and as
acknowledged by the authors—this population was better nourished
than the average population and thus, the study does not provide much
insight to the possible benefit in individuals with poor vitamin C status
or risk factors of stroke and CVD.
The EPICOR study represents the Italian segment of the European
Prospective Investigation into Cancer and Nutrition (EPIC) study cohort
and investigated the possible correlation between estimated vitamin C
intake and ischemic stroke [80]. The study found that vitamin C was
significantly associated with decreased risk of ischemic stroke. The
study used an estimated total antioxidant capacity as the primary out-
come and thus, correlations with vitamin C intake was the results of a
sub-analysis. Total antioxidant capacity is a very crude measure—and
in this case an indirect estimate—of countless more or less important
molecules displaying antioxidant activity. While it may possible be
considered a surrogate marker of fruit intake, many other components
including coffee and wine were also showed to contribute considerably
[80]. A severe weakness of the study is the very low number of total
stroke cases amounting to only 194 per 328,553 person years ex-
amined. Moreover, the estimated vitamin C intake was only estimated
once at baseline. Consequently, the study does not account for any
dietary changes over the almost 8 year follow-up period.
The Iowa Women's Health Study assessed the possible correlation
between estimated vitamin C intake and mortality from stroke in
postmenopausal women [81]. No association between vitamin C intake
and death from stroke was observed. The study population was part of a
random sample of Iowa women with driver's license. The validity of the
FFQ also used in the in the Nurses' Health study mentioned above [73]
was done by comparing mean intakes from five 24-h dietary recalls
with responses from the food-frequency questionnaire in a subgroup of
44 women [82]. Consequently, they were not assessed for correlation to
plasma vitamin C status. The correlation coefficients for the comparison
of the two methods of diet assessment for intakes of vitamin C was 0.53
for food only and 0.76 for combined intake from food and supplements
[81]. Again, only one estimate at baseline was performed.
Collectively, the above studies are all very large and with con-
siderable follow-up periods. However, they were all designed as broad
purposed population surveys without the specific intention of studying
effects of vitamin C intake. The three largest studies have clear selection
bias towards well-nourished individuals, i.e. health care professionals
and teachers. This severely limit their usefulness in identifying asso-
ciations between vitamin C status and disease, as vitamin C intake
above average has very little impact on systemic vitamin C status. Also
most of them only included a single baseline estimate of vitamin C
intake, which may seriously misrepresent dietary patterns and changes
during the study period but even more importantly also the life-long
dietary habits leading up to the study that could potentially have a
stronger impact on disease risk. Finally, the potential for residual
confounding with regard to vitamin C is expectedly relative high, as the
correlation between vitamin C intakes and status is low particularly at
high intakes.
5.2. Observational studies measuring vitamin C status
Limiting the examination to studies measuring blood vitamin C
status rather than estimating vitamin C intake using FFQs or food dia-
ries should, at least in theory, improve the scientific quality con-
siderably. These studies are summarized in Table 4. The EPIC-Norfolk
survey have given rise to a considerable number of studies including
two on vitamin C [83,84]. Both prospective cohort studies included
about 20,000 men and women. The first study examined the possible
relationship between all-cause, cardiovascular disease, ischemic heart
disease and cancer mortality after four years [84]. The study showed
that vitamin C status was significantly inversely correlated to all-cause
mortality as well as mortality due to cardiovascular disease and is-
chemic heart disease. The data also revealed a clear concentration-re-
sponse relationship: For each 20 μmol/L rise in plasma vitamin C
concentration, a 20% reduction in risk of all-cause mortality could be
observed (p<0·0001). The risk of death was about half in the top
compared to bottom quintile with respect to vitamin C status. The
findings are impressive considering the short follow-up period of only
four years. However, as with most of the previously mentioned studies,
vitamin C (status in this case) was only assessed a single time at base-
line. With the short duration though, chances of markedly changed
dietary habits diminishes but are still relevant. Moreover, the study did
not adjust for social class and physical activity as these data were not
available at the time of analysis. The second EPIC-Norfolk investigated
the relationship between plasma vitamin C status and risk of stroke with
a follow-up period of nearly ten years [83]. The study found a 42%
lower risk of stroke in the top compared to bottom quartile of vitamin C
status. The study was based on 448 incidents of stroke per 196,713
person years, i.e. about a 4-fold higher incidence than in the EPICOR
study mentioned above. Both studies quantified vitamin C using a
fluorometric assay after derivatization. These assays are known to have
less accuracy and precision than methods based on high-performance
liquid chromatography [67]. However, if meticulous sample handling
has been applied, a general over or underestimation of samples would
not affect the study outcome and the potentially increased variation
would only attenuate the significance of the differences observed. Both
studies used non-fasted blood samples, which generally overestimates
vitamin C status.
Data from the Second National Health and Nutrition Examination
Survey (NHANES II) were used as basis for the following three studies.
Simon et al. examined the relationship between serum ascorbic acid
and cause-specific mortality [85]. They reported a trend towards de-
creased risk of CVD in people with normal or high compared to low
vitamin C levels and a 25% decreased risk of all-cause mortality. From
another NHANES II study, they concluded that serum vitamin C status
was independently associated with lower risk of stroke and chronic
heart disease [86]. A non-linear concentration-response relationship
between vitamin C concentration and risk of both conditions was found
with an expected particular higher effect of vitamin C deficiency. Loria
et al. examined the same cohort and found that the bottom quartile of
serum vitamin C levels had 57% increased risk of all-cause death and
62% increased risk of cancer death compared to the top quartile [87].
While Simon et al. reported a significantly lower cancer risk in men
with high vitamin C status, they unexpectedly found a higher risk in
women with high levels of vitamin C [85]. However, this difference was
not observed by Loria and coworkers using the same cohort [87]. All
the studies assessed vitamin C in serum from non-fasted blood samples
using a colorimetric assay.
Collectively, the above studies are large with mixed follow-up
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periods. They appear to have less selection bias than the FFQ based
studies discussed above. Interestingly, all studies found a significant
relationship between high vitamin C status and decreased risk of mor-
bidity or mortality. Thus, a potential selection bias towards healthy
enrollees would likely have attenuated the effect. However, the five
studies are based on only two different population surveys and there-
fore essentially only represent two separate studies. All studies suffer
from less than optimal analytical methodology, in part explainable by
the very large number of samples and era of analysis, but potentially
leading to increased risk of over- or under-estimation of vitamin C.
They have all used non-fasted blood samples as basis for the vitamin C
measurement generally leading to an overestimation of the vitamin C
status. Also, they do not account for possible confounding from po-
tential multiple micronutrient deficiencies that could impact the re-
levance of the correlations.
5.3. Randomized controlled trials using vitamin C in the intervention
5.3.1. The Linxian study
The major RCTs using vitamin C in their intervention are summar-
ized in Table 5. The Linxian study was the first major RCT to study the
effect of antioxidant and mineral intervention [88]. The setting of
Linxian, China, was chosen because of its high esophageal cancer rate
and poor general nutritional status of the population. In a complex ½
(2 × 2 x 2 × 2) design, the authors aimed to test the combined effect of
nine vitamins and minerals in a fractional design, where all participants
received one of seven combinations of four grouped supplements or
placebo for 5.25 yrs. The vitamin C supplement (120 mg/day) was
combined with Molybdenum (30μg/day). No effect of vitamin C and
molybdenum was observed on mortality and cancer incidence [88].
Baseline vitamin C levels were assessed 10 months prior to study start
in 49 individuals allocated to supplements and 49 allocated to placebo
both of which indicated severe vitamin C deficiency, however, with
intervention group participants being significantly lower than placebo
(p<0.03). A blood sample during the intervention trial was obtained
from 730 to 740 individuals from intervention and placebo groups,
respectively. Expectedly, the vitamin C status improved significantly
over placebo to 46 μmol/L in the intervention group (p<0.001) but
surprisingly, the vitamin C status of the placebo group also showed a
highly significant increase to 30.7 μmol/L from baseline (p<0.001),
indicating that both groups were in the suboptimal range at this point
[2] and clearly increased from study start. It was not reported if the
placebo group was allowed to take concurrent supplements but con-
sidering their suboptimal status, supplement use is probably unlikely to
have been widespread. The Linxian study is interesting as it is the only
major RCT that have allegedly included vitamin C deficient subjects.
However, the significantly increased vitamin C status in the placebo
group raises serious concerns. This suggests either that the baseline
levels were severely underestimated in the very small sample of in-
dividuals analyzed at study start, e.g. by coincidence, poor analytical
methodology or inappropriate sample handling, or that the placebo
group improved their diet during intervention, e.g. by diet change or
concurrent supplementation. Regardless of the reason, the change in
the placebo group severely limits the study's ability to assess the effect
of the vitamin C intervention. Another major concern is the amount of
vitamin C in the supplement. At the time of the study, the RDA for
vitamin C was 60 mg/day and the supplement included twice that
amount, i.e. 120 mg/day. It appears highly questionable if such a
limited amount of vitamin C—which was clearly insufficient to nor-
malize the vitamin C status of the intervention group—could be ex-
pected to result in a change in morbidity or mortality over a time span
of only 5 years compared to the impact of a presumed life-time of severe
vitamin C deficiency. Also, a 25-year post-trial follow-up of the trial
expectedly showed no effect of the 5.25 year supplementation period
[89]. Ta
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5.3.2. The British Heart Protection Study
The British Heart Protection Study investigated the effect of a
multivitamin supplement containing 600 mg vitamin E, 250 mg vitamin
C, and 20 mg β-carotene daily vs placebo for five years in a high risk
population of men and women with coronary disease, other occlusive
arterial disease, or diabetes in a 2 × 2 design also including simvastatin
[75]. No significant reductions in the 5-year mortality from, or in-
cidence of, any type of vascular disease, cancer, or other major outcome
were observed from the antioxidant intervention. Vitamin C status was
not measured at study start but judging from the assessment of vitamin
C status in non-fasted blood samples at follow-up—carried out in about
5% of the participants—the participants were not vitamin C deficient
prior to supplementation. However, the intervention did produce a
significant 15.7 μmol/L increase in vitamin C status compared to pla-
cebo, 58.9 vs 43.2 μmol/L. The methodology used for vitamin C de-
termination or sample handling is not reported. All participants were
allowed to continue any prior supplement use during the study period
except for high dose vitamin E. The number of concurrent supplement
users in each allocation group was not reported. From the use of non-
fasted blood samples, the vitamin C status of the study population is
likely somewhat overestimated. In spite of this, it is worth noticing that
the vitamin C supplement used was clearly insufficient to saturate those
allocated to intervention, thus resulting in partly overlapping popula-
tions. Again, the relatively short duration and modest size of the in-
tervention has to be compared to the high-risk status of the study po-
pulation and their life-time dietary and supplement history that is not
known or accounted for in order to judge if it is reasonable to expect a
study effect under these conditions. Based on the available information,
this appears highly questionable.
5.3.3. The Physician's Health Study II
The Physician's Health Study II RCT investigated the effect of eight
years of supplementation with vitamin C (500mg/day) and vitamin E
(400IU every other day) vs placebo on cardiovascular disease risk in
14641 male physicians aged ≥50 years in a 2 × 2 design [76]. Vitamin
C supplementation did not reduce the risk of major cardiovascular
events in this period. The vitamin C status of the study participants was
not assessed either at entry or during or post intervention. This ser-
iously limits the possibility of reexamining and concluding on the data,
as the potential effect of the 500 mg/day vitamin C supplementation on
the vitamin C status of the individual may vary from highly significant
to negligible depending on their entry level and dietary habits. Also, a
potential bias between groups cannot be excluded. Furthermore, the
study participants were allowed to take concurrent supplements up to
the RDA during the trial. Concurrent supplement use was reported only
if used for more than a month per year. These numbers were only 4.4%
among the placebos.
5.3.4. The SU.VI.MAX study
The SU.VI.MAX study was carried out in French men and women
slightly younger than those of the other studies (≥35 yrs) [90]. The
study tested the efficacy a daily multivitamin and mineral supplement
containing nutritional doses of vitamin C (120 mg), vitamin E (30 mg), β-
carotene (6 mg), selenium (100 μg) and zinc (20 mg) vs placebo in a
parallel design for 7.5 years in reducing the incidence of cancer and is-
chemic heart disease in the general population. Although the study
showed no significant effect on the main outcome, a sub analysis did
reveal a significant positive effect of supplementation on cancer in-
cidence [p<0.008) and all-cause mortality (p<0.02) in men [90]. The
authors attributed this gender effect to the generally lower vitamin C
status among men. Vitamin C status at entry was assessed in fasted blood
samples from ‘an unselected subsample’ and showed that participants
were adequate although not entirely saturated with vitamin C at entry.
Intervention produced a slight albeit significant increase in plasma vi-
tamin C status compared to placebo and the placebo group was not al-
lowed to take concurrent supplements. Although carefully designed with
respect to several of the pitfalls mentioned earlier, the present study has
several shortcomings in terms of investigating the potential of vitamin C
supplementation on human disease risk. Thus, the serious selection bias
in terms of well-nourished individuals with a relatively high vitamin C
status combined with the low-dose supplement limits the likelihood of
identifying an effect of supplementation. The 120 mg vitamin C per day
provided in the supplement has probably been close to or less than that
ingested through the diet of the study participants in general. Moreover,
the positive effect observed in men cannot be directly attributed to the
vitamin C supplementation as vitamin C was not provided as a single
supplement. In spite of these limitations, the SU.VI.MAX study ade-
quately demonstrates that limited if any effect of low-dose supple-
mentation can be expected in already well-nourished individuals with an
adequate vitamin C intake. However, it would have been highly inter-
esting had the study been conducted in a vitamin C deficient population
with a 500–1000 mg/day vitamin C supplement.
5.3.5. The Women's Antioxidant Cardiovascular Study
The final major intervention study using vitamin C reexamined
here—The Women's Antioxidant Cardiovascular Study—investigated
the effects of ascorbic acid (500 mg/d), vitamin E (600 IU every other
day), and beta carotene (50 mg every other day) on the combined
outcome of myocardial infarction, stroke, coronary revascularization,
or CVD death among 8171 female health professionals 40 years or older
at increased risk of CVD in a 2 × 2 x 2 factorial design for 9.4 years
[74]. The study found no overall effects of vitamin C, vitamin E, or beta
carotene on cardiovascular events. Vitamin C status of the study po-
pulation was not recorded at entry. Judging from the assessment in ‘30
local participants' about halfway through the study [74], the study
population—including the placebo group—was saturated in vitamin C
throughout the study. Although not reported in the paper, it would
appear from the high vitamin C status (in particular in the intervention
group) that fasted blood samples were clearly not obtained. Also,
concurrent supplement use up to the RDA was allowed in the study
population and 27.5% of the placebo group reported taking supple-
ments during the trial. In spite of the amount of vitamin C provided as
supplement in the present study, the inadequate inclusion and exclusion
criteria used only allows for the conclusion that additional vitamin C
supplementation to already saturated high-risk individuals does not
provide further protection from CVD.
Collectively, the above studies suffer from serious deficiencies pre-
venting them from drawing relevant conclusions on the potential ben-
efit of vitamin C supplementation in particular in populations with poor
vitamin C status. All except one study allowed the placebo group to take
concurrent supplements and three of the five examined only the com-
bined effect of a multivitamin cocktail with low dose vitamin C. Study
placebo participants mostly showed adequate to saturated levels of
vitamin C if measured and in the Linxian study that supposedly ex-
amined a population with poor nutrition, vitamin C levels almost tri-
pled in the placebo group during the study (Table 5).
6. Concluding remarks
As exemplified above, clinical studies examining the relationship be-
tween vitamin C and health, disease and mortality—or indeed the effect of
supplementation—generally suffer from many limitations that seriously
impair their ability to draw conclusions on the importance of vitamin C in
human health. In epidemiological studies, a baseline assessment of vitamin
C status may represent the lifestyle of the individual and thus be an in-
dication of life-long exposure, although this is far from certain as diet
changes are not accounted for. In intervention studies, the intervention
arm(s) represent a change in lifestyle, the impact of which has to be
compared to that of the life-long exposure prior to the intervention. In that
perspective, the intervention periods and doses appear completely in-
adequate to robustly identify a putative benefit of supplementation, in
particular when looking at populations that are not low or deficient in
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vitamin C. Thus, when reexamining the clinical literature on vitamin C,
one is left with little certainty and many questions, including those pre-
sented in the introduction:What is the optimal intake of vitamin C and what
is its preventive and therapeutic potential?
Collectively, there seems to be a relatively persistent association
between poor vitamin C status and increased risk of disease and pre-
mature death. However, it is not known if this increased risk of mor-
bidity and mortality from vitamin C deficiency is a result of lack of
vitamin C per se, multiple co-deficiencies or deficiencies in other sub-
stances than vitamin C. The intervention studies may serve to demon-
strate that supplementation with vitamin C to already saturated in-
dividuals apparently has little or no effect on morbidity and mortality.
However, it remains unknown if supplementation with vitamin C to
individuals with poor vitamin C status can prevent disease development
or progression. A possible way of adding new information to this
complex issue could be to recruit individuals with genetically un-
favorable SNPs in SVCTs. These individuals are likely to represent a life-
long poorer vitamin C status without abundant co-deficiencies.
Consequently, it would be possible study their risk of vitamin C defi-
ciency attributable diseases. However, as it is probably not possible to
counteract the negative effect of a SNP lowering the vitamin C home-
ostasis by supplementation, these individuals are not particularly suited
for intervention studies. A major challenge with this type of studies is
that the frequency of these SNPs is very low resulting in relatively low
power in spite of enormous populations. Thus, well-designed studies are
(still) needed to explore the putative role of vitamin C deficiency in
disease development and progression and the potential benefit of sup-
plementation to individuals with poor nutritional status.
Finally, biological signatures for vitamin C action, i.e. biomarkers or
combination of biomarkers that specifically and robustly reflect a
condition, are desperately needed to improve the assessment of phy-
siologically sufficient/insufficient vitamin C status and the potential
concentration-response relationship between vitamin C status and
specific diseases. So far, very limited knowledge is available on the
relationship between vitamin C status and the function of the individual
physiological processes for which vitamin C provides the reducing
equivalents in vivo. From animal studies, it is known that a ‘hierarchy’
of the tissues/organs exists that determines which part of the body that
get the vitamin C if limited resources are available [26,27,31,91–93].
These show that e.g. the brain is clearly prioritized during periods with
inadequate supply of vitamin C. Importantly, such prioritization may
have serious implications for the clinical effect of vitamin C deficiency
and suboptimal vitamin C status. Thus, very limited amounts of vitamin
C are necessary to prevent scurvy, suggesting a highly favorable con-
centration/response relationship for the underlying physiological me-
chanisms. However, the potential prioritization between the vitamin C
dependent processes required to maintain e.g. cardiovascular function,
immune system and neuronal health remains unknown. The elucidation
of such disease specific concentration-effect relationships require highly
robust biological signatures not yet available.
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